S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:SRDX

Surmodics (SRDX) Stock Forecast, Price & News

$17.67
-0.06 (-0.34%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$17.43
$17.83
50-Day Range
$17.13
$24.23
52-Week Range
$16.00
$40.21
Volume
62,800 shs
Average Volume
147,071 shs
Market Capitalization
$249.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00

Surmodics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
166.0% Upside
$47.00 Price Target
Short Interest
Healthy
1.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.52
Upright™ Environmental Score
News Sentiment
0.63mentions of Surmodics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

265th out of 1,010 stocks

Surgical & Medical Instruments Industry

26th out of 104 stocks


SRDX stock logo

About Surmodics (NASDAQ:SRDX) Stock

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Stock News Headlines

Surmodics (NASDAQ:SRDX) Now Covered by StockNews.com
The Largest Ever Technology Wave Is Coming!
This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Surmodics (SRDX) Scheduled to Post Earnings on Wednesday
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Company Calendar

Last Earnings
2/06/2023
Today
5/30/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:SRDX
CUSIP
86887310
Employees
389
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+166.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-27,270,000.00
Pretax Margin
-28.50%

Debt

Sales & Book Value

Annual Sales
$99.95 million
Book Value
$7.75 per share

Miscellaneous

Free Float
13,073,000
Market Cap
$249.68 million
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • Gary R. MaharajGary R. Maharaj
    President, Chief Executive Officer & Director
  • Timothy J. Arens
    CFO, SVP-Finance & Information Technology
  • Charles W. OlsonCharles W. Olson
    President-Medical Device Coatings & SVP
  • Teri L. W. Sides
    President-Vascular Interventions & SVP
  • John D. Manders
    Vice President-Finance & Controller













SRDX Stock - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings
or view top-rated stocks.

What is Surmodics' stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month target prices for Surmodics' stock. Their SRDX share price forecasts range from $34.00 to $60.00. On average, they anticipate the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price.
View analysts price targets for SRDX
or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2023?

Surmodics' stock was trading at $34.12 at the start of the year. Since then, SRDX shares have decreased by 48.2% and is now trading at $17.67.
View the best growth stocks for 2023 here
.

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our SRDX earnings forecast
.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings data on Monday, February, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.13. The firm earned $24.93 million during the quarter, compared to analyst estimates of $24.19 million. Surmodics had a negative net margin of 34.92% and a negative trailing twelve-month return on equity of 18.98%. During the same period in the prior year, the firm posted ($0.13) earnings per share.

What ETFs hold Surmodics' stock?

ETFs with the largest weight of Surmodics (NASDAQ:SRDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Equipment ETF (XHE).iShares U.S. Medical Devices ETF (IHI) and

What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of -$1.98--$1.68 for the period, compared to the consensus estimate of -$1.90. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $104.34 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Trigran Investments Inc. (16.69%), BlackRock Inc. (7.18%), Renaissance Technologies LLC (4.48%), Dimensional Fund Advisors LP (3.00%), State Street Corp (2.55%) and Segall Bryant & Hamill LLC (2.31%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends
.

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $17.67.

How much money does Surmodics make?

Surmodics (NASDAQ:SRDX) has a market capitalization of $249.68 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

How many employees does Surmodics have?

The company employs 389 workers across the globe.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.

This page (NASDAQ:SRDX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -